Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Cancer Incidences - Current and Future Projection

4. Cancer Market Outlook: Current and Future
     4.1 Cancer Generics: Market Size

5. Market Drivers and Trends
     5.1 Indian Generics Getting Marketing Approval in US
     5.2 Increasing Cancer Prevalence: Driving Generics Market
     5.3 Strategic Activity and Alliances on the Rise
     5.4 Patent Expiration Continue to Boost Generics Market
     5.5 Companies Thriving for New Cancer Generics

6. Cancer Generics: Market Segmentation by Disease Type
     6.1 Lung Cancer
            6.1.1 Current and Future Incidence
            6.1.2 Regional Analysis
            6.1.3 Commercialized Drugs: Branded and Generics
     6.2 Breast Cancer
            6.2.1 Current and Future Incidence
            6.2.2 Regional Analysis
            6.2.3 Commercialized Drugs: Branded and Generics
     6.3 Colorectal Cancer
            6.3.1 Current and Future Incidence
            6.3.2 Regional Analysis
            6.3.3 Commercialized Drugs: Branded and Generics
     6.4 Stomach Cancer
            6.4.1 Current and Future Incidence
            6.4.2 Regional Analysis
            6.4.3 Commercialized Drugs: Branded and Generics
     6.5 Prostate Cancer
            6.5.1 Current and Future Incidence
            6.5.2 Regional Analysis
            6.5.3 Commercialized Drugs: Branded and Generics

7. Cancer Generic Drugs: Market Segmentation by Oral and Injectables
     7.1 Oral Generic Drugs
            7.1.1 Arimidex (Anastrozole)
            7.1.2 Casodex (Bicalutamide)
            7.1.3 Aromasin (Exemestane)
            7.1.4 Femara (Letrozole)
            7.1.5 Megace (Megestrol Acetate)
            7.1.6 Purinethol (Mercaptopurine)
            7.1.7 Tarceva (Erlotinib)
            7.1.8 Nolvadex (Tamoxifen Citrate)
            7.1.9 Eulexin (Flutamide)
            7.1.10 Hydrea (Hydroxyurea)
     7.2 Generic Injectables
            7.2.1 Camptosar (Irinotecan Hydrochloride)
            7.2.2 Velcade (Bortezomib)
            7.2.3 Taxotere (Docetaxel)
            7.2.4 Gemzar (Gemcitabine Hydrochloride)
            7.2.5 Doxil (Liposomal)
            7.2.6 Ifex (Ifosfamide)

8. Key Players
     8.1 Actavis Inc.
     8.2 Mylan
     8.3 Roxane Laboratories
     8.4 Accord Healthcare
     8.5 Sun Pharmaceuticals
     8.6 Teva
     8.7 Fresnius Kabi